20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Veradermics, Incorporated (MANE) operates in the BIOTECHNOLOGY industry and is headquartered in New Haven, United States with about 37 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, MANE reported $0M in revenue and ($70M) in net income.
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M |
| Operating Income (EBIT) | ($95M) | ($72M) | ($27M) | ($17M) |
| Operating Margin % | — | — | — | — |
| Net Income | ($85M) | ($70M) | ($26M) | ($16M) |
| Net Margin % | — | — | — | — |
| EBITDA | — | ($70M) | ($26M) | ($16M) |
| Earnings Per Share (EPS) | — | $-2.00 | $-0.13 | $-0.08 |
| Shares Outstanding (M) | 40M | 35M | 201M | 201M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($30M) | ($30M) | ($23M) | ($13M) | ($6M) |
| Operating Margin % | — | — | — | — | — |
| Net Income | ($24M) | ($27M) | ($22M) | ($12M) | ($6M) |
| Net Margin % | — | — | — | — | — |
| EBITDA | ($30M) | ($27M) | ($21M) | — | ($5M) |
| Earnings Per Share (EPS) | $-0.58 | $-0.73 | $-0.59 | — | $-0.03 |
| Shares Outstanding (M) | 40M | 37M | 37M | — | 201M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($73M) | ($72M) | ($24M) | ($14M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($73M) | ($72M) | ($24M) | ($14M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($14M) | ($21M) | ($24M) | ($13M) | ($4M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($15M) | ($21M) | ($24M) | ($13M) | ($4M) |
| FCF Margin % | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets | $826M | $153M | $59M | $18M |
| Cash & Cash Equivalents | $319M | $22M | $53M | $16M |
| Total Liabilities | $12M | $274M | $5M | $4M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $1M |
| Total Shareholders' Equity | $814M | ($121M) | $55M | $15M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MANE viewer.
About TickerBase · Data methodology & sources · Privacy · Terms